Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes

M.C. Gillies; R.J. Walton; J.M. Simpson; J.J. Arnold; R.H. Guymer; Ian Mcallister; A.P. Hunyor; R.W. Essex; Nigel Morlet; D. Barthelmes

doi:10.1167/iovs.13-11993

Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes

M.C. Gillies, R.J. Walton, J.M. Simpson, J.J. Arnold, R.H. Guymer, Ian Mcallister, A.P. Hunyor, R.W. Essex, Nigel Morlet, D. Barthelmes

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

PURPOSE: We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative age-related macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice.

METHODS: Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression.

RESULTS: Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections.

CONCLUSIONS: These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice.

Original language	English
Pages (from-to)	5754-5760
Number of pages	7
Journal	Investigative Ophthalmology and Visual Science
Volume	54
Issue number	8
Early online date	2 Jul 2013
DOIs	https://doi.org/10.1167/iovs.13-11993 https://doi.org/10.1167/iovs.13-11993
Publication status	Published - 27 Aug 2013

Access to Document

Cite this

Gillies, M. C., Walton, R. J., Simpson, J. M., Arnold, J. J., Guymer, R. H., Mcallister, I., Hunyor, A. P., Essex, R. W., Morlet, N., & Barthelmes, D. (2013). Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. Investigative Ophthalmology and Visual Science, 54(8), 5754-5760. https://doi.org/10.1167/iovs.13-11993, https://doi.org/10.1167/iovs.13-11993

@article{37670ec8286c4671b36dfec658b1c213,

title = "Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes",

abstract = "PURPOSE: We report the 12-month outcomes of 1140 treatment-na{\"i}ve eyes with exudative age-related macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice.METHODS: Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression.RESULTS: Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections.CONCLUSIONS: These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice.",

keywords = "Aged, Aged, 80 and over, Angiogenesis Inhibitors/adverse effects, Antibodies, Monoclonal, Humanized/adverse effects, Australia, Bevacizumab, Clinical Audit, Exudates and Transudates, Female, Humans, Macular Degeneration/drug therapy, Male, Prospective Studies, Ranibizumab, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Visual Acuity",

author = "M.C. Gillies and R.J. Walton and J.M. Simpson and J.J. Arnold and R.H. Guymer and Ian Mcallister and A.P. Hunyor and R.W. Essex and Nigel Morlet and D. Barthelmes",

year = "2013",

month = aug,

day = "27",

doi = "10.1167/iovs.13-11993",

language = "English",

volume = "54",

pages = "5754--5760",

journal = "Investigative Ophthalmology & Visual Science (IOVS)",

issn = "0146-0404",

publisher = "Association for Research in Vision and Ophthalmology (ARVO)",

number = "8",

}

Gillies, MC, Walton, RJ, Simpson, JM, Arnold, JJ, Guymer, RH, Mcallister, I, Hunyor, AP, Essex, RW, Morlet, N & Barthelmes, D 2013, 'Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes', Investigative Ophthalmology and Visual Science, vol. 54, no. 8, pp. 5754-5760. https://doi.org/10.1167/iovs.13-11993, https://doi.org/10.1167/iovs.13-11993

TY - JOUR

T1 - Prospective audit of exudative age-related macular degeneration

T2 - 12-month outcomes in treatment-naive eyes

AU - Gillies, M.C.

AU - Walton, R.J.

AU - Simpson, J.M.

AU - Arnold, J.J.

AU - Guymer, R.H.

AU - Mcallister, Ian

AU - Hunyor, A.P.

AU - Essex, R.W.

AU - Morlet, Nigel

AU - Barthelmes, D.

PY - 2013/8/27

Y1 - 2013/8/27

N2 - PURPOSE: We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative age-related macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice.METHODS: Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression.RESULTS: Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections.CONCLUSIONS: These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice.

AB - PURPOSE: We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative age-related macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice.METHODS: Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression.RESULTS: Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections.CONCLUSIONS: These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice.

KW - Aged

KW - Aged, 80 and over

KW - Angiogenesis Inhibitors/adverse effects

KW - Antibodies, Monoclonal, Humanized/adverse effects

KW - Australia

KW - Bevacizumab

KW - Clinical Audit

KW - Exudates and Transudates

KW - Female

KW - Humans

KW - Macular Degeneration/drug therapy

KW - Male

KW - Prospective Studies

KW - Ranibizumab

KW - Vascular Endothelial Growth Factor A/antagonists & inhibitors

KW - Visual Acuity

U2 - 10.1167/iovs.13-11993

DO - 10.1167/iovs.13-11993

M3 - Article

C2 - 23821201

VL - 54

SP - 5754

EP - 5760

JO - Investigative Ophthalmology & Visual Science (IOVS)

JF - Investigative Ophthalmology & Visual Science (IOVS)

SN - 0146-0404

IS - 8

ER -

Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes

Abstract

Access to Document

Fingerprint

Cite this